Arrowhead Pharmaceuticals Inc

Latest Report Overview

Arrowhead Pharmaceuticals Inc (ARWR) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q3 FY2026) revenue of $75 million with diluted EPS of $-1.36 and net income of $-194 million. Operating margin was -226.0%, and free cash flow was $-181 million for the period. Management continues to prioritize the advancement of its TRiM-based pipeline, focusing on pipeline progression in cardiometabolic and other therapeutic areas. The high variability in quarterly revenue highlights the company's reliance on periodic milestone payments from strategic collaborations. Operating margins remain heavily compressed by significant R&D investments, which are necessary to fuel the platform’s long-term potential but weigh heavily on short-term liquidity. The company’s liquidity position is a central theme, with cash on hand of $50.66 million set against over $1.2 billion in debt. Future financial performance will be largely contingent on achieving clinical milestones that trigger further payments from partners or the successful entry into commercial-stage operations for its internal programs.

Key Takeaways for Arrowhead Pharmaceuticals Inc

• Revenue volatility remains high, with +171% YoY growth in fiscal Q3 2026 driven by irregular milestone payments from collaboration partners.
• Financial position is strained with only $50.66M in cash against $1.26B in debt, necessitating either new capital raises or substantial milestone achievement.
• R&D expenditure remains the primary cash drain at ~$189.25M for the quarter, reflecting an aggressive investment strategy in clinical-stage RNAi programs.
• The business model is structurally dependent on R&D collaborations (e.g., GSK, Takeda), creating a lack of predictable, recurring commercial revenue streams.
• Clinical execution is the primary existential risk; the company faces stiff competition from established RNAi leaders like Alnylam Pharmaceuticals.
• Operating margins and free cash flow remain deeply negative, reflecting the company’s status as a pre-commercial or early-commercial stage innovator.

What Does Arrowhead Pharmaceuticals Inc Do?

Arrowhead Pharmaceuticals is a biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to deliver RNA interference (RNAi) triggers to specific cell types, primarily in the liver. This platform is designed to overcome historical delivery challenges associated with RNAi therapeutics. Arrowhead partners with global pharmaceutical companies to co-develop and commercialize its programs, while also maintaining a portfolio of proprietary assets. The company operates entirely within the biotechnology industry, focusing on high-unmet-need areas like cardiometabolic disease, liver disease, and rare genetic disorders. With a R&D-heavy operational structure, Arrowhead leverages a network of clinical trial sites and manufacturing partners to advance its late-stage pipeline, aiming to transform genetic medicine through gene silencing.